Jubilant Life Sciences
Jubilant Life Sciences, a prominent player in the pharmaceutical and life sciences sector, is headquartered in Noida, India. Founded in 1978, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in contract manufacturing, active pharmaceutical ingredients (APIs), and drug delivery solutions, Jubilant Life Sciences is recognised for its commitment to quality and innovation. The company’s core offerings, which include a diverse range of generic pharmaceuticals and specialty chemicals, set it apart in a competitive market. With a focus on sustainability and advanced technology, Jubilant Life Sciences has achieved significant milestones, including multiple regulatory approvals and partnerships with leading global firms. This positions the company as a trusted partner in the healthcare industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does Jubilant Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jubilant Life Sciences's score of 35 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jubilant Life Sciences's reported carbon emissions
In 2023, Jubilant Life Sciences reported total carbon emissions of approximately 66,229,600 kg CO2e, comprising 8,492,000 kg CO2e from Scope 1, 54,703,000 kg CO2e from Scope 2, and 662,296,000 kg CO2e from Scope 3 emissions. This reflects a significant reliance on Scope 3 emissions, which include indirect emissions from the supply chain and product use. Over the years, the company has shown a trend of reducing its Scope 1 and Scope 2 emissions. For instance, in 2019, Scope 1 emissions were about 808,300,000 kg CO2e, which decreased to approximately 18,140,000 kg CO2e by 2021. Similarly, Scope 2 emissions decreased from about 158,070,000 kg CO2e in 2019 to approximately 85,840,000 kg CO2e in 2021. Despite these reductions, there are currently no specific reduction targets or commitments disclosed by Jubilant Life Sciences, such as those aligned with the Science Based Targets initiative (SBTi). The company continues to focus on improving its sustainability practices, although further details on future climate commitments remain unspecified. Overall, Jubilant Life Sciences is actively working towards reducing its carbon footprint, particularly in direct emissions, while facing challenges in managing its extensive Scope 3 emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jubilant Life Sciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
